Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 14, 2022
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain Sep 26, 2022
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis Sep 6, 2022
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results Aug 16, 2022
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder Jul 20, 2022
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder Jul 18, 2022
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence Jun 14, 2022
